Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA deficient ovarian cancer

被引：0
|
作者：
Yang, Shicheng
Brown, Needa
Campbell, Abigail L.
Aggarwal, Kushi
Dinulescu, Daniela M.
Sridhar, Srinivas
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1994
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1994
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
    Yang, Shicheng
    Green, Allen
    Brown, Needa
    Robinson, Alexis
    Senat, Merline
    Testino, Bryanna
    Dinulescu, Daniela M.
    Sridhar, Srinivas
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Developing a nanoformulation of the PARP inhibitor talazoparib as a novel delivery for treatment of BRCA-deficient breast cancer
    Zhang, Di
    Baldwin, Paige
    Sridhar, Srinivas
    Liby, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
    Di Zhang
    Bijay Singh
    Jessica Moerland
    Owen Mitchell
    Lizbeth Lockwood
    Sarah Carapellucci
    Srinivas Sridhar
    Karen T. Liby
    Scientific Reports, 11
  • [4] Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
    Zhang, Di
    Singh, Bijay
    Moerland, Jessica
    Mitchell, Owen
    Lockwood, Lizbeth
    Carapellucci, Sarah
    Sridhar, Srinivas
    Liby, Karen T.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Localized delivery of the PARP inhibitor Talazoparib for chemoprevention of breast cancer
    Zhang, Di
    Singh, Bijay
    Moerland, Jessica
    Mitchell, Owen
    Lockwood, Lizbeth
    Carapellucci, Sarah
    Sridhar, Srinivas
    Liby, Karen
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
    Belz, Jodi E.
    Kumar, Rajiv
    Baldwin, Paige
    Ojo, Noelle Castilla
    Leal, Ana S.
    Royce, Darlene B.
    Zhang, Di
    van de Ven, Anne L.
    Liby, Karen T.
    Sridhar, Srinivas
    THERANOSTICS, 2017, 7 (17): : 4340 - 4349
  • [7] Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
    Hobbs, Evthokia A.
    Litton, Jennifer K.
    Yap, Timothy A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1825 - 1837
  • [8] Nanoformulated Talazoparib enhances the efficacy and reduces the toxicity of this PARP inhibitor in a preclinical model of BRCA-deficient breast cancer
    Zhang, Di
    Baldwin, Paige
    Sridhar, Srinivas
    Liby, Karen
    FASEB JOURNAL, 2018, 32 (01):
  • [9] Sustained release of PARP inhibitor Talazoparib and chemotherapeutics from biodegradable implants for treatment of breast and prostate cancer
    Belz, Jodi
    Ojo, Noelle Castilla
    Baldwin, Paige
    Kumar, Rajiv
    van de Ven, Anne
    Liby, Karen
    Cormack, Robert
    Makrigiorgos, Mike
    Sridhar, Srinivas
    CANCER RESEARCH, 2016, 76
  • [10] Nanoformulations and sustained delivery systems for the PARP inhibitors Olaparib and Talazoparib
    Baldwin, Paige
    Ohman, Anders
    Belz, Jodi
    Thong, Jeremy
    Ojo, Noelle Castilla
    Liby, Karen
    Dinulescu, Daniela
    Sridhar, Srinivas
    CANCER RESEARCH, 2017, 77
12345